Gujarat Themis Biosyn credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025

160	160	29.9
154	154	17.3
0.56×	0.56×	0.12×
0.53×	0.53×	0.07×
2.12×	2.12×	0.43×
1.87×	2.04×	0.25×
21.23×	21.23×	174.37×
35.7%	35.7%	10.7%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

GUJTHEM₹375.80

Gujarat Themis Biosyn Limited

· Pharma & Health

₹ CrorePeersRPGLIFE GUFICBIO ORCHPHARMA UNICHEMLAB FDC IOLCP MOREPENLAB INNOVACAPMcap ₹4,095 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Total Debt	29.9	159.9	159.9
Net Debt	17.3	153.8	153.8
Total Debt/Equity	0.12	0.56	0.56
Net Debt/Equity	0.07	0.53	0.53
Total Debt/EBITDA	0.43	2.12	2.12
Net Debt/EBITDA	0.25	2.04	1.87
Interest Coverage (EBIT/Interest)	174.37	21.23	21.23
Total Debt/Total Capital %	10.74	35.71	35.71

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.